Valuation Newron Pharmaceuticals S.p.A. Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.60 EUR | +4.13% |
|
-.--% | -52.72% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
Company Valuation: Newron Pharmaceuticals S.p.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27.93 | 27.99 | 94.91 | 185.1 | 511.9 | 260.6 | - | - |
| Change | - | 0.21% | 239.07% | 94.99% | 176.62% | -49.09% | - | - |
| Enterprise Value (EV) 1 | 27.93 | 60.23 | 114.7 | 225.7 | 521.2 | 299.3 | 275.4 | 260.6 |
| Change | - | 115.64% | 90.45% | 96.77% | 130.92% | -42.57% | -8.01% | -5.34% |
| P/E | -1.86x | -1.6x | -5.84x | 11.2x | -38.9x | -9.23x | 33.9x | 4.33x |
| PBR | - | -2x | -3.17x | 130x | -46x | - | - | - |
| PEG | - | -0.1x | 0.82x | -0x | 0x | -0x | -0x | 0x |
| Capitalization / Revenue | 4.85x | 4.59x | 10.5x | 3.6x | 26.8x | 24x | 5.81x | 2.17x |
| EV / Revenue | 4.85x | 9.88x | 12.7x | 4.39x | 27.3x | 27.6x | 6.14x | 2.17x |
| EV / EBITDA | -2.3x | -4.6x | -10x | 8.56x | -115x | -7.1x | 6.09x | 2.77x |
| EV / EBIT | -2.26x | -4.53x | -9.86x | 8.62x | -111x | -9.92x | 27.4x | 2.77x |
| EV / FCF | - | -5.42x | -11.3x | -12.8x | 16.1x | 4.04x | 4.51x | 2.51x |
| FCF Yield | - | -18.4% | -8.85% | -7.81% | 6.2% | 24.7% | 22.2% | 39.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.84 | -0.98 | -0.91 | 0.85 | -0.66 | -1.358 | 0.37 | 2.89 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.762 | 6.094 | 9.057 | 51.39 | 19.13 | 10.84 | 44.83 | 120 |
| EBITDA 1 | -12.15 | -13.1 | -11.43 | 26.36 | -4.525 | -42.13 | 45.2 | 94 |
| EBIT 1 | -12.36 | -13.3 | -11.63 | 26.17 | -4.697 | -30.17 | 10.05 | 94 |
| Net income 1 | -14.9 | -17.49 | -16.22 | 15.84 | -13.24 | -31.17 | 5.023 | 58 |
| Net Debt 1 | - | 32.24 | 19.8 | 40.64 | 9.287 | 38.68 | 14.72 | - |
| Reference price 2 | 1.57 | 1.57 | 5.32 | 9.51 | 25.65 | 12.53 | 12.53 | 12.53 |
| Nbr of stocks (in thousands) | 17,845 | 17,845 | 17,845 | 19,459 | 19,961 | 20,806 | - | - |
| Announcement Date | 3/15/22 | 3/14/23 | 3/19/24 | 3/31/25 | 3/23/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 2x | 8.67x | 1.17% | 13.61B | |
| 25.02x | 1.86x | 11.41x | -.--% | 12.62B | |
| Average | 24.46x | 47.78x | 13.14x | 0.32% | 29.29B | |
| Weighted average by Cap. | 23.41x | 63.80x | 12.19x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
- Valuation Newron Pharmaceuticals S.p.A.
Select your edition
All financial news and data tailored to specific country editions
